Rockwood Holdings, Inc. Ends the Day Up Following Acquisition Announcement

Updated on

Rockwood Holdings, Inc. (NYSE:ROC), EXACT Sciences Corporation (NASDAQ:EXAS) and Sociedad Quimica y Minera de Chile (ADR) (NYSE:SQM) are the day’s top gainers on Wall Street this Tuesday. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), E2open Inc (NASDAQ:EOPN) and Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) are the losers.

Acquisition Deal Leads to Rockwood Holdings Surge

Rockwood Holdings, Inc. (NYSE:ROC) is today’s top gainer, its price climbing +9.82% after Albemarle agreed to acquire it in a $6.2 billion deal. Brazilian billionaire Jorge Lemann initiated a position in the specialty chemicals and advanced materials firm during the first quarter of the year, picking up 75,000 shares.

EXACT Sciences Corporation (NASDAQ:EXAS) climbed +5.9%. A new Q1 buy for George Soros, EXAS is a molecular diagnostics company. Its price has climbed +47.91% in 2014.

Sociedad Quimica y Minera de Chile (ADR) (NYSE:SQM), another first quarter Soros pick, surged +3.69% today. Zacks recently upgraded its rating of the firm from underperform to neutral, setting its price target at $29.00. SQM is up 13.95% YTD but down -2.61% over the past month.

AVEO Pharmaceuticals Takes a Dive

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is the day’s biggest loser, its price falling -10.64%. The long-time Seth Klarman pick has had a rough go in 2014, losing -30.6% of its value year-to-date. The scenario has, however, started to brighten over the past month.

E2open Inc (NASDAQ:EOPN) slipped -8.95% today as it continues to suffer the fall-out of Bank of America analyst Scott Shiao’s downgrade of the stock from a buy to neutral. The cloud-based enterprise solutions provider and Wilbur Ross holding has declined -23.84% over the past five days alone and is down -31.49% YTD.

Taking the third and final spot on today’s list of losers is Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC). It ended the day posting a loss of -7.6%. Yet another Wilbur Ross pick (the billionaire holds 116,000 CYCC assets), Cyclacel has remained relatively stable over the past month, its price up just +0.63% since 30 days ago. Year-to-date, however, is a different story, as CYCC is down -21.14% since the start of 2014.

Leave a Comment